Medical Condition News

RSS

New study demonstrates link between smoking and flat adenomas

According to a new study, smoking was found to have a strong association with the presence of flat adenomas (precancerous polyps) in the colon and may explain the earlier onset of colorectal cancer in smokers, as well as the advanced stage with which they present when compared to nonsmokers. Flat adenomas are more difficult to detect and have more aggressive pathology than the typical raised type of polyp detected during colorectal cancer screening.

11 Jun 2010

DZNE, MRC and CIHR sign cooperation agreement for research on neurodegenerative diseases

Representatives of the German Centre for Neurodegenerative Diseases, the UK Medical Research Council and the Canadian Institutes of Health Research today signed a cooperation agreement that aims to establish and apply harmonised guidelines and technologies for research on neurodegenerative diseases.

11 Jun 2010

Reprogrammed killer cells prevent metastasis

A team of researchers has developed a method to produce cells that kill tumour cells in the lab and prevent tumours forming in mouse models of cancer. Although the current work is in cells and mouse, if the research transfers to human biology, the new type of cell could be a new source for cell-based anticancer therapies.

11 Jun 2010

Programme on surgical and medical treatment strategies for cancer

The 5th ESU Master class on medical treatment for urological cancer is organised by the European School of Urology (ESU) on 25-27 June 2010 at the Barcel- Hotel Sants in Barcelona, Spain.

11 Jun 2010

PPMD to fund two promising research initiatives in Duchenne muscular dystrophy

Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that PPMD will be funding two critical, promising research initiatives in Duchenne.

11 Jun 2010

mPFC dysfunction contributes to compulsive seeking of sexual behavior

Sex "addiction" is a concept that has had particularly high visibility recently with the publicity associated with Tiger Woods. Persons with addictive or compulsive disorders frequently display an inability to inhibit behaviors once they become maladaptive, despite adverse consequences of their behavior. The medial prefrontal cortex (mPFC) is a brain region involved in decision-making and behavioral flexibility, and it has been identified as a potential mediator of behavioral inhibition.

11 Jun 2010

Office-based duplex guided hemodialysis access angioplasty safe: Study

Duplex guided dialysis access angioplasty can be performed safely and effectively in the office setting according to a new study presented today at the 64th Vascular Annual Meeting presented by the Society for Vascular Surgery®. According to researchers, ultrasound offers the advantage of treating the patient without ionizing radiation and sedation or iodinated contrast.

11 Jun 2010

Hypertension linked to severity of bipolar disorders

Nearly half of patients hospitalized with bipolar disorder may suffer from hypertension, and the younger a person is diagnosed with the psychiatric condition the more likely they are to develop high blood pressure, according to a recent Michigan State University study.

11 Jun 2010

Bevacizumab effective for treatment of wet AMD: Study

An inexpensive, but unlicensed drug to help prevent severe sight loss in older people has been shown to be safe and effective, finds a study published on bmj.com today.

11 Jun 2010

Sharron Davies unveils new Nottingham Respiratory BRU Clinical Trials Unit

Olympic swimmer and television personality Sharron Davies MBE was in Nottingham this week to open a new clinical trials unit that will take treatments for respiratory illnesses such as asthma from laboratory bench to bedside.

11 Jun 2010

Botox reduces short-term pain in thoracic outlet syndrome patients

Made popular for its ability to smooth wrinkles when injected into the face, Botox - a toxin known to weaken or paralyze certain nerves and muscles - may have another use that goes beyond the cosmetic.

11 Jun 2010

Type 2 diabetes doubles risk of cancer in women

Type 2 adult-onset diabetes causes insulin-like hormones to circulate through the body. A new study finds this has a surprisingly positive effect on reducing the rate of prostate cancer in men, but is bad news for women: Type 2 diabetes may double the risk of female genital and other cancers.

11 Jun 2010

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

MannKind Corporation today announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin, also combined with basal insulin, in reducing HbA1c levels in subjects with inadequately controlled Type 1 diabetes.

11 Jun 2010

Study identifies mechanism that interrupts normal p53 gene function leading to tumor development

The p53 gene has been a well-documented player in the prevention of tumors. It is considered the most frequently mutated gene in human tumors with more than half harboring p53 mutations (Bennett et al., 1999). These mutations often can be caused by disruption in normal p53 function.

11 Jun 2010

APP Pharmaceuticals to commence marketing of Oxaliplatin Injection in U.S

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg.

11 Jun 2010

Bevacizumab increases risk for proteinuria in cancer patients

Cancer patients treated with the chemotherapy agent bevacizumab (Avastin) may be at an increased risk of severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment. This conclusion stems from a study of more than 12,000 patients by Shenhong Wu, M.D., Ph.D., Principal Investigator, and colleagues at Stony Brook University Medical Center. Their findings are reported in online June 10 in the Journal of the American Society Nephrology (JASN).

11 Jun 2010

Phase 3 AVERROES clinical trial of apixaban for atrial fibrillation closes early due to clear evidence of efficacy

Bristol-Myers Squibb Company and Pfizer today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin.

11 Jun 2010

FDA advisory committee recommends approval of Novartis' FTY720 for relapsing MS

Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease. The FDA has the option of seeking the advice of one of its advisory committees as it reviews and decides whether to approve a new treatment. The committee voted unanimously that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and that safety of the proposed 0.5 mg dose justified approval.

11 Jun 2010

Remote monitoring and nurse case management combined improve health of Medicare beneficiaries with CHF

Chronic heart failure (CHF) is one of the most common causes of hospitalization for elderly Americans, and is also one of the nation's most costly conditions to treat.

10 Jun 2010

EC approves Nivestim for prevention of FN

Hospira announced today that the EC has approved Nivestim™ (filgrastim) for the prevention of FN, the most serious haematological toxicity that occurs as a result of cancer chemotherapy. Nivestim now has marketing authorisation in all EU member states. Nivestim is expected to reduce the cost of neutropenia treatment.

10 Jun 2010